News
»
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S. Vivacelle Bio, Inc. provided support for the investigational new drug application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S.
Latest News
(BPRW) McDonald’s USA ® Joins Forces with Elaine Welteroth & Fashion Industry Experts to Elevate Emerging Black Designers
(BPRW) Old Navy Captures The Essence Of ‘Summering’ With Tracee Ellis Ross & Yara Shahidi
(BPRW) The 2024 ESSENCE Festival of Culture™ Celebrates 30 Years of Loving Us with Evening Performances from USHER for a Special One-Night Only 20th Anniversary of Confessions Milestone Moment, Janet Jackson, Charlie Wilson, Victoria Monét...
(BPRW) Tech Visionary and Trailblazing Innovator Edwige A. Robinson to Address Graduates at DeVry University’s Commencements